Treatment | Preclinical MSRs | Preclinical HRs | Clinical OS HRs | Clinical PFS HRs | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Estimate | 95% CI | Estimate | 95% CI | Estimate | 95% CI | Estimate | 95% CI | |||||
LB | UB | LB | UB | LB | UB | LB | LB | |||||
Anti-CTLA-4 | 0.82 | 0.78 | 0.86 | 0.30 | 0.17 | 0.53 | 0.88 | 0.76 | 1.01 | 0.76 | 0.54 | 1.08 |
Anti-PD-1 | 0.84 | 0.80 | 0.88 | 0.31 | 0.18 | 0.55 | 0.77 | 0.73 | 0.82 | 0.89 | 0.79 | 1.00 |
Anti-PD-L1 | 0.83 | 0.79 | 0.87 | 0.30 | 0.17 | 0.54 | 0.86 | 0.79 | 0.93 | 1.04 | 0.87 | 1.23 |
Anti-CTLA-4 + anti-PD-1 | 0.82 | 0.75 | 0.89 | 0.36 | 0.20 | 0.66 | 0.71 | 0.62 | 0.81 | 0.64 | 0.45 | 0.90 |
Anti-CTLA-4 + anti-PD-L1 | 0.79 | 0.67 | 0.93 | 0.36 | 0.20 | 0.66 | 0.87 | 0.74 | 1.03 | 1.03 | 0.73 | 1.46 |
Anti-CTLA4 + Chemotherapy | 0.80 | 0.54 | 1.20 | 0.31 | 0.10 | 0.99 | 0.87 | 0.75 | 1.01 | 0.86 | 0.57 | 1.30 |
Anti-PD-1 + Chemotherapy | 0.63 | 0.53 | 0.76 | 0.17 | 0.08 | 0.38 | 0.73 | 0.66 | 0.82 | 0.69 | 0.55 | 0.87 |
Anti-PD-L1 + Chemotherapy | 0.86 | 0.58 | 1.25 | 0.20 | 0.07 | 0.60 | 0.82 | 0.73 | 0.91 | 0.71 | 0.56 | 0.88 |